Request Legal Help Now - Free


$3.78 Million Dilantin Settlement Following Death of 9-Year-Old Girl

This is a settlement for the SJS, Stevens Johnson Syndrome lawsuit.

New York, NY: A $3.78 million settlement with pharmaceutical manufacturer Pfizer Inc on behalf of the family of a nine-year-old New York girl who died in June 2004 as the result of a drug-induced disease known as Stevens Johnson Syndrome, which caused all of her skin to peel off.

The settlement approval was filed Friday following a hearing before New York State Supreme Court Judge Judith H. Gische.

Jesse Nichols Jacobson died less than a month after receiving the Pfizer-produced drugs Dilantin and Flagyl. Dilantin is an anti-seizure drug and Flagyl is an anti-fungal medication. Shortly after the administration of the drugs, Ms. Jacobson developed a drug-induced condition known as toxic epidermal necrolysis or TEN, which causes a severe rash and leads to the loss of 30 percent to 100 percent of a patient's skin, often followed by infections, blindness or death.

A study compiled by 15 burn centers in the U.S. revealed that more than 20 percent of TEN cases are believed to be caused by Dilantin use, with deaths reported in approximately one of every four cases. Dilantin is one of the most commonly-prescribed anti-seizure drugs in the U.S., and has been marketed by Pfizer and its predecessor companies since 1936.

In Canada and other countries, Pfizer warns that patients with African ancestry have a higher risk for developing Dilantin Hypersensitivity Syndrome which can include TEN, but Pfizer has not bothered warning doctors and patients in the United States, said the lawyer for the estate and adoptive parents of Ms. Jacobson. He added that Pfizer's label does not advise clinicians that a drug-company sponsored survey of seizure clinicians concluded that Dilantin should virtually never be used as a first line anti-seizure drug for children.

Legal Help

If you have a similar problem and would like to be contacted by a lawyer at no cost or obligation, please fill in our form.
Published on Oct-15-10


Fields marked * are mandatory. Please read our comment guidelines before posting.


Note: Your name will be published with your comment.

*Email Address:

Your email will only be used if a response is needed.
*Your Comment:

Are you the defendant or a subject matter expert on this topic with an opposing viewpoint? We'd love to hear your comments here as well, or if you'd like to contact us for an interview please submit your details here.

Request Legal Help Now! - Free